Alumis Completes Merger with ACELYRIN
Alumis Inc. (NASDAQ: ALMS) has completed its merger with ACELYRIN, Inc., creating a leading clinical-stage biopharma company focused on immune-mediated diseases. Under the merger terms, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share. ACELYRIN's stock has been delisted from NASDAQ.
The merger significantly strengthens Alumis' balance sheet, extending its cash runway into 2027. The combined company aims to advance its late-stage portfolio through multiple planned key data readouts. Morgan Stanley advised Alumis, while Guggenheim Securities advised ACELYRIN in the transaction.
Alumis Inc. (NASDAQ: ALMS) ha completato la fusione con ACELYRIN, Inc., dando vita a una società biofarmaceutica clinica leader focalizzata sulle malattie mediate dal sistema immunitario. Secondo i termini della fusione, gli azionisti di ACELYRIN riceveranno 0,4814 azioni di azioni ordinarie Alumis per ogni azione ACELYRIN posseduta. Le azioni di ACELYRIN sono state rimosse dalla quotazione NASDAQ.
La fusione rafforza significativamente il bilancio di Alumis, estendendo la liquidità disponibile fino al 2027. La società combinata punta a far progredire il suo portafoglio in fase avanzata attraverso molteplici comunicazioni chiave di dati previste. Morgan Stanley ha assistito Alumis, mentre Guggenheim Securities ha consigliato ACELYRIN nell’operazione.
Alumis Inc. (NASDAQ: ALMS) ha completado su fusión con ACELYRIN, Inc., creando una empresa biofarmacéutica en etapa clínica líder enfocada en enfermedades mediadas por el sistema inmunológico. Según los términos de la fusión, los accionistas de ACELYRIN recibirán 0.4814 acciones de acciones comunes de Alumis por cada acción de ACELYRIN. Las acciones de ACELYRIN han sido retiradas del NASDAQ.
La fusión fortalece significativamente el balance de Alumis, extendiendo su liquidez hasta 2027. La empresa combinada busca avanzar su cartera en etapas avanzadas mediante múltiples divulgaciones clave de datos planificadas. Morgan Stanley asesoró a Alumis, mientras que Guggenheim Securities asesoró a ACELYRIN en la transacción.
Alumis Inc. (NASDAQ: ALMS)는 ACELYRIN, Inc.과의 합병을 완료하여 면역 매개 질환에 중점을 둔 선도적인 임상 단계 바이오제약 회사를 설립했습니다. 합병 조건에 따라 ACELYRIN 주주들은 ACELYRIN 주식 1주당 Alumis 보통주 0.4814주를 받게 됩니다. ACELYRIN 주식은 NASDAQ에서 상장 폐지되었습니다.
이번 합병으로 Alumis의 재무 상태가 크게 강화되어 현금 유동성이 2027년까지 연장되었습니다. 합병된 회사는 여러 주요 데이터 공개를 통해 후기 단계 포트폴리오를 진전시키는 것을 목표로 하고 있습니다. Morgan Stanley는 Alumis를 자문했으며, Guggenheim Securities는 ACELYRIN을 자문했습니다.
Alumis Inc. (NASDAQ : ALMS) a finalisé sa fusion avec ACELYRIN, Inc., créant une société biopharmaceutique en phase clinique de premier plan, spécialisée dans les maladies à médiation immunitaire. Selon les termes de la fusion, les actionnaires d’ACELYRIN recevront 0,4814 actions ordinaires Alumis pour chaque action ACELYRIN détenue. Les actions d’ACELYRIN ont été retirées du NASDAQ.
Cette fusion renforce considérablement la situation financière d’Alumis, prolongeant sa trésorerie jusqu’en 2027. La société combinée vise à faire progresser son portefeuille en phase avancée grâce à plusieurs publications clés de données prévues. Morgan Stanley a conseillé Alumis, tandis que Guggenheim Securities a conseillé ACELYRIN dans cette opération.
Alumis Inc. (NASDAQ: ALMS) hat die Fusion mit ACELYRIN, Inc. abgeschlossen und damit ein führendes biopharmazeutisches Unternehmen in der klinischen Phase geschaffen, das sich auf immunvermittelte Krankheiten spezialisiert. Gemäß den Fusionsbedingungen erhalten ACELYRIN-Aktionäre für jede ACELYRIN-Aktie 0,4814 Aktien von Alumis-Stammaktien. Die ACELYRIN-Aktien wurden vom NASDAQ entfernt.
Die Fusion stärkt die Bilanz von Alumis erheblich und verlängert die Liquiditätsdauer bis 2027. Das kombinierte Unternehmen plant, sein Portfolio in der Spätphase durch mehrere geplante wichtige Datenveröffentlichungen voranzutreiben. Morgan Stanley beriet Alumis, während Guggenheim Securities ACELYRIN bei der Transaktion unterstützte.
- Extended cash runway into 2027, providing strong financial stability
- Strengthened balance sheet through merger
- Enhanced ability to advance late-stage portfolio through multiple planned data readouts
- Creation of a leading clinical-stage biopharma company with differentiated portfolio
- Dilution for existing Alumis shareholders due to share issuance to ACELYRIN stockholders
- Integration risks and challenges combining two companies
Establishes leading clinical stage biopharma company with differentiated portfolio of therapies and strong balance sheet
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it has completed its merger with ACELYRIN, Inc.
Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned. ACELYRIN common stock has ceased trading and will no longer be listed on the NASDAQ Global Select Market.
“We are excited to complete our merger and move forward with a significantly strengthened balance sheet to support Alumis’ differentiated late-stage portfolio and develop transformative therapies for patients,” said Martin Babler, President, CEO and Chairman of Alumis. “This merger allows us to advance our pipeline through multiple planned key data readouts, with a cash runway that now extends into 2027. We will remain disciplined across our operations and capital plan as we deliver on the significant benefits of the merger for our patients and stockholders alike.”
Advisors
Morgan Stanley & Co. LLC served as financial advisor to Alumis, and Cooley LLP served as its legal counsel. Guggenheim Securities, LLC served as financial advisor to ACELYRIN, and Fenwick & West LLP and Paul Hastings LLP served as its legal counsel.
About Alumis
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. All statements, other than statements of historical facts, including express or implied statements regarding the issuance of common stock of Alumis in connection with the merger; the expected benefits of the merger; the sufficiency of Alumis’ capital resources; Alumis’ ability to efficiently advance its clinical pipeline; and any assumptions underlying any of the foregoing, are forward-looking statements. Any forward-looking statements in this press release are based on Alumis’ current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in Alumis’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to Alumis’ ability to advance ESK-001 and to obtain regulatory approval of and ultimately commercialize Alumis’ clinical candidates, the timing and results of preclinical and clinical trials, Alumis’ ability to fund development activities and achieve development goals, Alumis’ ability to protect its intellectual property and other risks and uncertainties described in Alumis’ filings with the Securities and Exchange Commission (SEC), including any future reports Alumis may file with the SEC from time to time. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Alumis Contacts Investor Relations Teri Dahlman Red House Communications teri@redhousecomms.com Or Media Jim Golden / Jack Kelleher / Tali Epstein Collected Strategies Alumis-CS@collectedstrategies.com
FAQ
What is the exchange ratio in the Alumis (ALMS) and ACELYRIN merger?
How long does Alumis (ALMS) expect its cash runway to last after the merger?
Who were the financial advisors for the Alumis-ACELYRIN merger?
What is the main focus area of the merged Alumis company?
What happened to ACELYRIN's stock after the merger with Alumis?
